logo
BYD's upcoming 3,000 hp Yangwang U9 ‘Track Edition' leaves all electric supercars behind

BYD's upcoming 3,000 hp Yangwang U9 ‘Track Edition' leaves all electric supercars behind

Yahoo8 hours ago
The Chinese Ministry of Industry and Information Technology (MIIT) has revealed that EV giant BYD is all set release a Track Edition of its Yangwang U9 2-door coupe electric supercar. This new variant will effectively triple the U9's already impressive performance to a mighty 3,019 hp (2,251 kW).
For reference, 'Track Editions' of cars typically feature changes to body design for better aerodynamics and added downforce, but also often feature bigger brakes.
The current Yangwang U9 uses four motors to provide around 1,300 hp (970 kW). However, BYD seems to have upgraded this with new 555 kW motors at each of the four wheels for its planned new edition, according to details filed with China's MIIT.
That much power makes the new U9 more powerful than any current production electric hypercar. In fact, it surpasses other supercars like the Lotus Evija (1,972 hp) and Rimac Nevera (1,914 hp) by a large margin.
Balancing old with the new
Weighing 5,467 pounds (2,480 kg), the Yangwang U9 Track Edition will only be about 441 pounds (200 kg) heavier than the Rimac Nevera, which has much less power.
The new U9 will measure between 16.3 feet (4.97 meters) and 16.37 feet (4.99 meters) in length, and 6.6 feet (2 meters) in width. It will likely also be between 4.3 feet (1.311 meters) and 4.43 feet (1.351 meters) in height, with a 9.51 feet (2.9 meters) wheelbase.
According to reports, the U9 Track Edition will mostly retain the built design of the existing base model, featuring a glossy red and black exterior, 20-inch wheels with 325/35 R20 tyres, carbon-fibre roof, a large fixed carbon-fibre rear wing and a range of aerodynamic options.
https://www.youtube.com/watch?v=MPX3l5Gblrk&pp=ygUQVHJhY2sgRWRpdGlvbiB1OQ%3D%3D
Meanwhile, the current U9 model uses an 80 kWh lithium iron phosphate BYD Blade battery, delivering a CLTC-rated range of 280 miles (450 km). Other features include a 500 kW DC fast-charging capability, enabling a 30% to 80% state-of-charge in about 10 minutes. The Yangwang U9's suspension is BYD's 'DiSus-X' system, capable of extreme moves like hopping over potholes or driving on three wheels.
Perfecting an already impressive car
Although additional specifications of the upcoming Track Edition can be gleamed from the existing base model, a good number of details are missing from the MIIT filing.
While the current U9 can accelerate from 0 to 62 mph (0–100 kph) in 2.36 seconds, the Track Edition could potentially rival or beat the Nürburgring lap record for road-legal cars, currently held by Mercedes-AMG One.
The base model has already achieved a lap time of 7 minutes and 17.9 seconds in November 2024 at Germany's Nürburgring Nordschleife. For reference, the top speed for the old model is already clocked at 243.5 mph (391.94 kph).
The upgraded U9 might most likely race faster but details are yet to be made public. There is also no mention of a price tag, but the existing base model will set you back about $233,411 (1.68 million Yuan).
From the filing it appears that the upcoming variant is not just a 'track package' U9 with spoilers. Instead, it promises to be a massively updated electric hypercar, which could challenge the fastest petrol-powered cars in history while also showcasing how extreme Chinese EV engineering has become.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Compounding Pharmacy Market and Pharma Manufacturing Poised for Strong, Parallel Growth by 2030
Compounding Pharmacy Market and Pharma Manufacturing Poised for Strong, Parallel Growth by 2030

Yahoo

time9 minutes ago

  • Yahoo

Compounding Pharmacy Market and Pharma Manufacturing Poised for Strong, Parallel Growth by 2030

HYDERABAD, India, Aug. 11, 2025 /PRNewswire/ -- Mordor Intelligence recently released comprehensive reports on compounding pharmacy market and pharma manufacturing industry, detailing robust growth trajectories for both sectors. Driven by increasing demand for personalized therapies and advanced production technologies, these markets are set to expand significantly through 2030, creating strategic opportunities for stakeholders across the healthcare value chain. Compounding Pharmacy Market Outlook The compounding pharmacy market, valued at approximately USD 15.1 billion in 2025, is forecast to reach nearly USD 20 billion by 2030, registering a compound annual growth rate (CAGR) of 5.7%, says Mordor Intelligence. Growth stems from rising demand for customized medications, chronic pain management alternatives, and expanded bio-identical hormone therapies. Personalized formulations for pediatric and geriatric patients further bolster market uptake, ensuring precise dosing and improved adherence. "Our analysis indicates that the compounding sector is becoming a vital component of modern therapeutics," according to the Mordor Intelligence report on compounding pharmacies. "Continued API localization and advanced sterile workflows are key to meeting growing volumes while maintaining rigorous quality standards." For more details on the compounding pharmacy market report, visit: Key Drivers Behind Compounding Pharmacy Growth Personalized Medication Demand: Tailored pain-management mixes and hormone therapies address individual patient needs. Regulatory Frameworks: Guidelines permitting compounding during commercial drug shortages enhance market resilience. Technological Integration: Automated sterile systems and digital quality assurance streamline high-volume operations. Pharmaceutical Manufacturing Market Dynamics According to Mordor Intelligence, the pharmaceutical manufacturing market stands at roughly USD 506 billion in 2025 and is expected to ascend to approximately USD 811 billion by 2030, exhibiting a CAGR of 9.9%. Growth is anchored by reshoring incentives, continuous manufacturing adoption, and expansion of biosimilar capacity. Investment in AI-driven quality-control systems and modular plant designs accelerates time-to-market and supports diversified supply chains. "Advanced production technologies and regulatory support for continuous processes are transforming manufacturing economics," as per Mordor Intelligence's pharma manufacturing research report. "These trends enable manufacturers to balance scale with flexibility, essential for both blockbuster and niche therapies." For more details on the pharmaceutical manufacturing market report, visit: Emerging Trends in Pharmaceutical Manufacturing Continuous Processing Adoption: Cutting facility footprints and operating costs, supported by clear regulatory pathways. Biosimilar Surge: Patent expirations drive contract development and manufacturing organization (CDMO) engagement. Digital Integration: AI, IoT, and automation improve throughput, predictive maintenance, and batch-release timelines. Synergies and Market Implications Together, the rapid expansion of compounding pharmacies and the modernization of pharmaceutical manufacturing underscore a broader shift toward personalized, efficient, and resilient healthcare supply chains. Stakeholders—from CXOs and business analysts to healthcare research institutes—should monitor these intersecting markets for strategic partnerships, investment opportunities, and supply-chain optimizations. As these markets evolve, organizations equipped with actionable intelligence can capitalize on specialized formulations and advanced manufacturing capabilities. Mordor Intelligence's dual insights drive informed decision-making, empowering clients to navigate complexity and achieve sustainable growth in an increasingly competitive landscape. Explore more reports on the healthcare industry at Related Reports: Animal Drug Compounding Market: The market is projected to grow from USD 1.43 billion in 2025 to USD 2.04 billion by 2030 at a 7.4% CAGR. Growth is driven by personalized pet therapies, cannabinoid-based formulations, FDA-driven shortages, and AI-enabled compounding, while regulatory compliance and rising costs remain key Veterinary Drugs Market: The global market is projected to grow at a CAGR of 5.8%, driven by rising infectious diseases in pets and livestock, advancements in biologics, and increasing demand for animal-based products. The Lumpy Skin Disease (LSD) outbreak in Asia is accelerating vaccine R&D, with companies like Hester Biosciences developing vaccines to address this need. Such disease outbreaks and innovation efforts are expected to fuel market growth during the forecast OTC Drugs Market: The market is projected to grow from USD 195.96 billion in 2025 to USD 247.74 billion by 2030 at a 4.8% CAGR. Growth is driven by rising self-care trends, regulatory shifts enabling prescription-to-OTC switches, and demand for convenient formats like gummies and patches. Companies are adopting digital self-selection tools, track-and-trace technology, and omnichannel retail models to enhance trust and accessibility, especially in regions with high counterfeit risk. About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries, please contact:media@ 617-765-2493 Logo: View original content to download multimedia: SOURCE Mordor Intelligence Private Limited Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Lithium stocks soar after world's largest EV battery maker shutters mine in China
Lithium stocks soar after world's largest EV battery maker shutters mine in China

Yahoo

time9 minutes ago

  • Yahoo

Lithium stocks soar after world's largest EV battery maker shutters mine in China

Lithium stocks soared early Monday after the world's largest EV battery maker closed its lithium mine in China, sending lithium prices soaring. The spike in lithium companies' stocks comes after Contemporary Amperex Technology (C7A0.F) announced early Monday morning that it was halting operations at one of its most important mines in China — also one of the world's largest — after its permit for the mine expired. The company said the Jianxiawo mine, the largest in China's Yichun lithium hub, will be shuttered for three months while it seeks to renew its license, according to Bloomberg. CATL is the largest EV battery manufacturer in the world, holding more than a third of the market. Shares of Albemarle (ALB) and Sociedad Química y Minera (SQM), the two largest lithium producers in the world, were up more than 11% and 9%, respectively, in early trading. Fellow major lithium miners and processors Lithium Americas (LAC) and Sigma Lithium (SGML) were up over 8% and 16%, respectively. The price of spot lithium was up nearly 4% on Monday; lithium prices have risen over 15% in the past month. Elon Musk's Tesla (TSLA) is one of CATL's biggest customers, according to a report from the Shanghai Metals Market. Tesla stock was up 2% early Monday morning. In January, the US Department of Defense added CATL to a list of companies it says are affiliated with the Chinese military. This would ban the Defense Department from signing procurement contracts with the company beginning in June 2026 CATL's move to shutter its mine will likely be seen as reflective of Beijing's increasing crackdown on "involution," which it sees as a phenomenon where increasing competitive prices for resources like lithium are self-defeating and end up slowing development instead of spurring it, according to the Financial Times. Lithium's centrality to the global market has exploded over the past few years due to the metal's key role in electric vehicles, storage capacity on power grids, and a variety of electronics, including phones and laptops. Demand for the metal could grow by as much as 40% by 2040, according to a forecast from the International Energy Agency. Lithium prices had fallen sharply over the past couple of years, hitting their lowest level since 2021 in June after dropping 20% from the start of the year, as mines around the world have continued to produce the rare-earth metal even as output has outpaced demand. Production in China alone has risen by 55% since 2023, according to data from commodities pricing agency Fastmarkets. "At this time, we see limited upside in the short term with a lack of pricing and market dynamics change, but also limited downside as we believe the market has bottomed out," UBS analysts wrote in a July research note. "This leaves investors in a 'no man's land', where trading and taking positions into equities is challenging." Jake Conley is a breaking news reporter covering US equities for Yahoo Finance. Follow him on X at @byjakeconley or email him at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Nvidia, AMD Had to Make Deal With Trump, Ives Says
Nvidia, AMD Had to Make Deal With Trump, Ives Says

Yahoo

time9 minutes ago

  • Yahoo

Nvidia, AMD Had to Make Deal With Trump, Ives Says

Dan Ives of Wedbush Securities says Nvidia and AMD had no choice but agree on paying the US 15% of the revenue from sales of their AI chips to China. He says this is a game of high-stakes poker and these companies need access to the Chinese market. He speaks on "Bloomberg Surveillance." Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store